<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002109116</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.0001 par value</securitiesClassTitle>
      <dateOfEvent>03/09/2026</dateOfEvent>
      <previouslyFiledFlag>true</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001855485</issuerCIK>
        <issuerCUSIP>320703408</issuerCUSIP>
        <issuerName>Calidi Biotherapeutics, Inc.</issuerName>
        <address>
          <com:street1>4475 EXECUTIVE DRIVE</com:street1>
          <com:street2>SUITE 200</com:street2>
          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Chellsea Cartoscelli</personName>
          <personPhoneNum>9165040529</personPhoneNum>
          <personAddress>
            <com:street1>2315 Capitol Avenue</com:street1>
            <com:city>Sacramento</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>95816</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002109116</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Gavrilov Ognian Anguelov</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>700000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>700000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>700000.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.8</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, $0.0001 par value</securityTitle>
        <issuerName>Calidi Biotherapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>4475 EXECUTIVE DRIVE</com:street1>
          <com:street2>SUITE 200</com:street2>
          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Ognian Anguelov Gavrilov</filingPersonName>
        <principalBusinessAddress>2315 Capitol Avenue, Sacramento, CA 95816</principalBusinessAddress>
        <principalJob>Managing Partner, Gavrilov &amp; Brooks, 2315 Capitol Avenue, Sacramento, CA 95816</principalJob>
        <hasBeenConvicted>Not Applicable</hasBeenConvicted>
        <convictionDescription>Not Applicable</convictionDescription>
        <citizenship>United States of America </citizenship>
      </item2>
      <item3>
        <fundsSource>Personal Funds</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The Reporting Person acquired the Shares for investment purposes. The Reporting person may from time to time acquire additional shares of common stock or dispose of some or all of the shares in open market transactions, privately negotiated transactions, or otherwise. Except as set forth above, the Reporting Person currently has no plans or proposals which relate to or would result in any of the actions described in clauses a through j of item 3. </transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>700,000 (9.8%) </percentageOfClassSecurities>
        <numberOfShares>Sole voting power                         700,000
Shared voting powered              0
Sole dispositive power               700,000
Shared dispositive power         0</numberOfShares>
        <transactionDesc>None.</transactionDesc>
        <listOfShareholders>No person other than the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities.</listOfShareholders>
        <date5PercentOwnership>Not Applicable</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Not Applicable</contractDescription>
      </item6>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Gavrilov Ognian Anguelov</signatureReportingPerson>
        <signatureDetails>
          <signature>Ognian Anguelov Gavrilov</signature>
          <title>Managing Partner</title>
          <date>03/09/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
